Drug delivery and translational research

Using lipid nanoparticles to deliver full-length eys gene for retinal gene therapy despite size limits

Updated

Abstract

A non-viral lipid nanoparticle strategy successfully delivered full-length EYS plasmid DNA (~11.6 kb) for retinal gene therapy.

  • Gene augmentation for inherited retinal diseases is limited by the size of viral vectors, making large genes difficult to deliver.
  • The lipid nanoparticle formulation using ionizable lipid KC2 and DOPC demonstrated high encapsulation efficiency and effective gene expression.
  • Functional delivery of EYS was confirmed in retinal pigment epithelial cell cultures through imaging and gene expression analysis.
  • In ex vivo bovine retinal explants, EYS mRNA expression was detected after simulating subretinal injections, indicating successful delivery.
  • This approach is the first reported instance of delivering a large (>10 kbp) gene relevant to inherited retinal diseases using lipid nanoparticles.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Ethical standards: The experiments in this work comply with the current laws of the country in which they were performed. Competing interests: The authors have no relevant financial or non-financial interests to disclose. Informed consent and consent to participate: N/A Animal studies: No animal or human studies were carried out by the authors for this article. Consent to publish: N/A
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free